The collective activity of all six genes, which the researchers called the PHFScore, divided patients into groups with ...

A case report describes how persistent monocytosis documented over more than a year led clinicians to reclassify an ...

Research reveals that FDX1 downregulation in acute myeloid leukemia drives resistance to cuproptosis via the ROS/p53/ME1 axis ...

The activity of six different genes can help determine survival in patients with acute myeloid leukemia (AML), according to a ...

Aptevo Therapeutics Inc. announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in ...

PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026 ...

Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enzomenib (DSP-5336) for the treatment of patients ...

The exact cause of acute myeloid leukemia (AML) is unclear, but risk factors can include older age, radiation exposure, smoking, certain genetic conditions, and more. Acute myeloid leukemia (AML) is a ...

Researchers in Adelaide and Singapore have uncovered new clues as to why some people with chronic myeloid leukemia (CML) respond better to treatment than others, finding that mitochondrial function in ...

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or ...